TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Enlivex ( (ENLV) ).
On August 18, 2025, Enlivex Therapeutics announced positive three-month topline data from the Phase IIa stage of a clinical trial evaluating Allocetra™ in patients with moderate-to-severe knee osteoarthritis. The trial showed significant improvements in knee pain and function, with a favorable safety profile, indicating Allocetra™’s potential as a novel treatment in a market with significant unmet medical needs.
The most recent analyst rating on (ENLV) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Enlivex stock, see the ENLV Stock Forecast page.
Spark’s Take on ENLV Stock
According to Spark, TipRanks’ AI Analyst, ENLV is a Underperform.
Enlivex’s financial challenges, characterized by no revenue and ongoing cash burn, significantly impact its stock score. Technical indicators show neutral momentum, but the negative valuation metrics reflect ongoing financial difficulties. The absence of positive corporate events or earnings call data limits the potential for a higher score.
To see Spark’s full report on ENLV stock, click here.
More about Enlivex
Enlivex is a clinical-stage macrophage reprogramming immunotherapy company developing Allocetra™, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. This approach aims to rebalance the immune system and resolve life-threatening and debilitating conditions.
Average Trading Volume: 239,616
Technical Sentiment Signal: Buy
Current Market Cap: $43.41M
See more insights into ENLV stock on TipRanks’ Stock Analysis page.